Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVTX Avalo Therapeutics Inc

Pre-Market Trading 12-23 04:21:18 EST

8.91

-0.17

-1.87%

High9.81	Low8.67	Vol949.57K
Open9.10	D1 Closing9.08	Amplitude12.56%
Mkt Cap93.23M	Tradable Cap30.60M	Total Shares10.46M
T/O8.53M	T/O Rate27.65%	Tradable Shares3.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AVTX","market":"US","secType":"STK","nameCN":"Avalo Therapeutics Inc","latestPrice":8.91,"timestamp":1734728400000,"preClose":9.08,"halted":0,"volume":949569,"delay":0,"floatShares":3434100,"shares":10463633,"eps":-75.455154,"marketStatus":"Pre-Market Trading","change":-0.17,"latestTime":"12-23 04:21:18 EST","open":9.1,"high":9.81,"low":8.67,"amount":8534227.154953,"amplitude":0.125551,"askPrice":14.25,"askSize":200,"bidPrice":3.89,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-75.455154,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1734964200000},"marketStatusCode":1,"adr":0,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":8.91,"postHourTrading":{"tag":"盘后","latestPrice":8.91,"preClose":8.91,"latestTime":"16:56 EST","volume":91863,"amount":818501.02,"timestamp":1734731794726},"volumeRatio":7.462391827649066,"impliedVol":1.4551,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/AVTX","defaultTab":"news","newsList":[{"id":"2492245681","title":"BTIG Research Initiates Avalo Therapeutics With Buy Rating, $40 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2492245681","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492245681?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:28","pubTimestamp":1734611323,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics (AVTX) has an average rating of overweight and mean price target of $33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVTX","LENZ"],"gpt_icon":0},{"id":"2492261371","title":"Avalo Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Target Price $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2492261371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492261371?lang=en_us&edition=fundamental","pubTime":"2024-12-19 19:49","pubTimestamp":1734608967,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NK0SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2492954964","title":"Avalo Therapeutics Initiated at Buy by LUCID CAPITAL MARKETS","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954964","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954964?lang=en_us&edition=fundamental","pubTime":"2024-12-17 23:55","pubTimestamp":1734450900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AVTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2024 10:55 ET (15:55 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4555","BK4099","BK4596","BK4139","AVTX","LENZ"],"gpt_icon":0},{"id":"2492953164","title":"Avalo Therapeutics initiated with a Buy at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2492953164","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492953164?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:45","pubTimestamp":1734435938,"startTime":"0","endTime":"0","summary":"Lucid Capital analyst Dev Prasad initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $24 price target The company’s lead asset, A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-initiated-with-a-buy-at-lucid-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalo-therapeutics-initiated-with-a-buy-at-lucid-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4555","BK4596","LCID","AVTX","LENZ","BK4099","BK4551","BK4139"],"gpt_icon":0},{"id":"2490172945","title":"Avalo Therapeutics (AVTX) Is a Potential Hidden Gem With Significant Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2490172945","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490172945?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:22","pubTimestamp":1733746957,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics ($AVTX), a clinical-stage biotechnology company, is taking steps to treat immune dysregulation. The company’s lead asset, AVTX-0...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/avalo-therapeutics-avtx-is-a-potential-hidden-gem-with-significant-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/avalo-therapeutics-avtx-is-a-potential-hidden-gem-with-significant-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2483143020","title":"Avantium (AMS:AVTX) investors are sitting on a loss of 23% if they invested three years ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2483143020","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483143020?lang=en_us&edition=fundamental","pubTime":"2024-11-13 16:41","pubTimestamp":1731487288,"startTime":"0","endTime":"0","summary":"As an investor its worth striving to ensure your overall portfolio beats the market average. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. We regret to report that long term Avantium N.V.  shareholders have had that experience, with the share price dropping 43% in three years, versus a market decline of about 7.7%. Even worse, it's down 13% in about a month, which isn't fun at all. However, we note the price may have been impacted by the broader market, which is down 8.4% in the same time period.So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.Avantium shareholders are down 20% for the year, but the market itself is up 10%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/94bcc5bcuvrJNKUdDP7UgA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/58df37cadd48c6619bbe022c72dae85c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/94bcc5bcuvrJNKUdDP7UgA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/58df37cadd48c6619bbe022c72dae85c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avantium-ams-avtx-investors-sitting-084128255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AVTX","BK4123","BK4139","AVTXF","BK4196","AMS"],"gpt_icon":0},{"id":"2482708991","title":"Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2482708991","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482708991?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:00","pubTimestamp":1731412800,"startTime":"0","endTime":"0","summary":"Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 million. WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024  -- Avalo Therapeutics, Inc. , a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full exercise of the warrants issued in a March 2024 private placement.“We appreciate the outstanding support of our investors by fully exercising their warrants from the private placement earlier this year. While our primary focus remains on the execution of our Phase 2 LOTUS trial in hidradenitis suppurativa, we are excited to expand the AVTX-009 program into additional inflammatory indications,” said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. “We are hard at work identifying our next indication, the launch and execution of which will benefit from our improv","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d2A3qC7SG8Tok_kXv5MHIw--~B/aD0xMjIxO3c9MjI2OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4ff929bac6afa20af6c287a4c754c6ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d2A3qC7SG8Tok_kXv5MHIw--~B/aD0xMjIxO3c9MjI2OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4ff929bac6afa20af6c287a4c754c6ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avalo-therapeutics-receives-69-4-120000657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AN","LENZ","BK4214","BK4139","AVTX"],"gpt_icon":0},{"id":"2481187929","title":"Avalo Therapeutics GAAP EPS of -$2.83, revenue of $0.25M","url":"https://stock-news.laohu8.com/highlight/detail?id=2481187929","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481187929?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:34","pubTimestamp":1730990073,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics press release  : Q3  GAAP EPS of -$2.83.Cash position of approximately $82 million as of September 30, 2024 with subsequent receipt of approximately $58 million of warrant exercise proceeds in 4Q 2024, provides expected runway into at least 2027","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4261149-avalo-therapeutics-gaap-eps-of-2_83-revenue-of-0_25m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["AVTX"],"gpt_icon":0},{"id":"2481185796","title":"Avalo Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481185796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481185796?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:34","pubTimestamp":1730990073,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary  Avalo Therapeutics Inc AVTX.OQ reported a quarterly adjusted loss of $1.25 per share for the quarter en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL8N3ME2AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX"],"gpt_icon":0},{"id":"2481333906","title":"Avalo Therapeutics Q3 2024 GAAP EPS $(2.83) Misses $(1.19) Estimate, Cash Position Of Approximately $82M With Subsequent Receipt Of Approximately $58M Of Warrant Exercise Proceeds In 4Q 2024, Provides Expected Runway Into At Least 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2481333906","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481333906?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:33","pubTimestamp":1730982815,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(2.83) per share which missed the analyst consensus estimate of $(1.19) by 137.82 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41804197/avalo-therapeutics-q3-2024-gaap-eps-2-83-misses-1-19-estimate-cash-position-of-approximately-82m-wi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","LENZ"],"gpt_icon":0},{"id":"2481262903","title":"BRIEF-Avalo Reports Third Quarter 2024 Financial Results And Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481262903","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481262903?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:19","pubTimestamp":1730981995,"startTime":"0","endTime":"0","summary":"BRIEF-Avalo Reports Third Quarter 2024 Financial Results And Recent Business UpdatesNov 7 (Reuters) - Avalo Therapeutics Inc AVTX.O:AVALO REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUACFTMPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2481088499","title":"Avalo Therapeutics Q3 Product Revenue USD 249 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2481088499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481088499?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nPLXCF31B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2481903178","title":"Avalo Therapeutics: Cash and Cash Equivalents Were $81.9 Mln as of September 30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481903178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481903178?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUACFTMPN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2481908782","title":"Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481908782","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481908782?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980800,"startTime":"0","endTime":"0","summary":"Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa , with topline data expected in 2026. Cash position of approximately $82 million as of September 30, 2024 with subsequent receipt of approximately $58 million of warrant exercise proceeds in 4Q 2024, provides expected runway into at least 2027. WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2024  -- Avalo Therapeutics, Inc. , a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the third quarter of 2024.In October 2024, the first patient was dosed in the Phase 2 LOTUS trial for the treatment of HS.The Phase 2 LOTUS trial is a global study in approximately 180 adults with HS to assess the efficacy and safety of convenient subcutaneous bi-weekly and monthly dosing regimens of AVTX-009, compared to placebo.Avalo continues to evaluate AVTX-009 in additional immune-mediated diseases as it works toward the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d2A3qC7SG8Tok_kXv5MHIw--~B/aD0xMjIxO3c9MjI2OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4ff929bac6afa20af6c287a4c754c6ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d2A3qC7SG8Tok_kXv5MHIw--~B/aD0xMjIxO3c9MjI2OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/4ff929bac6afa20af6c287a4c754c6ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avalo-reports-third-quarter-2024-120000053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4214","AVTX","AN"],"gpt_icon":0},{"id":"2477684178","title":"HC Wainwright Initiates Avalo Therapeutics at Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2477684178","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477684178?lang=en_us&edition=fundamental","pubTime":"2024-10-24 19:57","pubTimestamp":1729771036,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates Avalo Therapeutics at Neutral","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVTX","LENZ"],"gpt_icon":0},{"id":"2477507357","title":"Cautious Outlook on Avalo Therapeutics Amid Early-Stage Development and Financial Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2477507357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477507357?lang=en_us&edition=fundamental","pubTime":"2024-10-24 18:15","pubTimestamp":1729764921,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics (AVTX) has received a new Hold rating, initiated by H.C. Wainwright analyst, Edward White. Edward White’s rating is based on a c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-outlook-on-avalo-therapeutics-amid-early-stage-development-and-financial-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-outlook-on-avalo-therapeutics-amid-early-stage-development-and-financial-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SSI","LENZ","AVTX"],"gpt_icon":0},{"id":"2477250461","title":"Avalo Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2477250461","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477250461?lang=en_us&edition=fundamental","pubTime":"2024-10-24 18:04","pubTimestamp":1729764241,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241024:nAZN2HZREI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2473609440","title":"Avalo Therapeutics Inc - Topline Data From Lotus Trial Expected in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2473609440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473609440?lang=en_us&edition=fundamental","pubTime":"2024-10-08 19:00","pubTimestamp":1728385201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241008:nTUA6GWNJ3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"gpt_icon":0},{"id":"2473501440","title":"Avalo Announces First Patient Dosed in Phase 2 Lotus Trial of Avtx-009 for the Treatment of Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2473501440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473501440?lang=en_us&edition=fundamental","pubTime":"2024-10-08 19:00","pubTimestamp":1728385201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241008:nTUA6GWNJ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"gpt_icon":0},{"id":"2473522440","title":"Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2473522440","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473522440?lang=en_us&edition=fundamental","pubTime":"2024-10-08 19:00","pubTimestamp":1728385200,"startTime":"0","endTime":"0","summary":"Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to placeboTopline data expected in 2026  WAYNE, Pa. a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/08/2959545/0/en/Avalo-Announces-First-Patient-Dosed-in-Phase-2-LOTUS-Trial-of-AVTX-009-for-the-Treatment-of-Hidradenitis-Suppurativa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX","AN","BK4214"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalotx.com","stockEarnings":[{"period":"1week","weight":-0.0347},{"period":"1month","weight":-0.1826},{"period":"3month","weight":-0.0833},{"period":"6month","weight":-0.3167},{"period":"1year","weight":-0.2575},{"period":"ytd","weight":-0.0209}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.073309},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.015784},{"month":3,"riseRate":0.222222,"avgChangeRate":0.34815},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.055213},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.055678},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.014626},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.036742},{"month":8,"riseRate":0.555556,"avgChangeRate":-0.058167},{"month":9,"riseRate":0.555556,"avgChangeRate":0.010251},{"month":10,"riseRate":0.555556,"avgChangeRate":0.13278},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.062453},{"month":12,"riseRate":0.3,"avgChangeRate":-0.032775}],"exchange":"NASDAQ","name":"Avalo Therapeutics Inc","nameEN":"Avalo Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avalo Therapeutics Inc,AVTX,Avalo Therapeutics Inc股票,Avalo Therapeutics Inc股票老虎,Avalo Therapeutics Inc股票老虎国际,Avalo Therapeutics Inc行情,Avalo Therapeutics Inc股票行情,Avalo Therapeutics Inc股价,Avalo Therapeutics Inc股市,Avalo Therapeutics Inc股票价格,Avalo Therapeutics Inc股票交易,Avalo Therapeutics Inc股票购买,Avalo Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction